Key Points
- Insider Mark Schoenberg sold 10,000 Urogen Pharma shares on November 19 at an average price of $25, netting $250,000 and reducing his position by 6.71% to 139,025 shares, according to an SEC filing.
- Urogen reported an EPS of ($0.69) (slightly beating estimates) but missed revenue expectations ($27.48M vs. $34.09M), the stock trades around $25 with a market cap near $1.18B, and analysts maintain a consensus Moderate Buy with an average target of $32.
Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 10,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the insider owned 139,025 shares of the company's stock, valued at approximately $3,475,625. The trade was a 6.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Mark Schoenberg also recently made the following trade(s):
- On Monday, September 8th, Mark Schoenberg sold 871 shares of Urogen Pharma stock. The stock was sold at an average price of $19.11, for a total transaction of $16,644.81.
Urogen Pharma Stock Performance
Shares of NASDAQ:URGN traded up $0.46 during trading on Friday, reaching $25.30. The stock had a trading volume of 127,506 shares, compared to its average volume of 1,449,659. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $26.28. The firm's fifty day moving average is $19.49 and its 200 day moving average is $15.92. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -7.29 and a beta of 1.06.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. The business had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. On average, research analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
URGN has been the topic of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Wall Street Zen raised Urogen Pharma from a "sell" rating to a "hold" rating in a research note on Saturday, November 8th. D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Piper Sandler initiated coverage on shares of Urogen Pharma in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 price objective for the company. Finally, HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.
View Our Latest Research Report on URGN
Institutional Investors Weigh In On Urogen Pharma
A number of institutional investors and hedge funds have recently made changes to their positions in URGN. Allianz Asset Management GmbH bought a new stake in Urogen Pharma during the 2nd quarter worth approximately $203,000. Bender Robert & Associates bought a new position in shares of Urogen Pharma in the second quarter valued at approximately $475,000. Truist Financial Corp bought a new position in shares of Urogen Pharma in the second quarter valued at approximately $423,000. Nuveen LLC bought a new stake in Urogen Pharma during the first quarter worth $1,028,000. Finally, Parkman Healthcare Partners LLC grew its holdings in Urogen Pharma by 6.3% during the first quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company's stock worth $4,348,000 after buying an additional 23,292 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
About Urogen Pharma
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
